Literature DB >> 26970955

CXCL12 is a key regulator in tumor microenvironment of cervical cancer: an in vitro study.

Suresh Singh Yadav1, Shyam Babu Prasad1, Chandra Bhushan Prasad1, Lakshmi Kant Pandey2, Satyajit Pradhan3, Sunita Singh4, Gopeshwar Narayan5.   

Abstract

CXCL12 is a small pro-inflammatory chemo-attractant cytokine which signals through chemokine receptor CXCR4. The importance of CXCL12/CXCR4 axis is coming to the fore in several divergent signaling pathway-initiating signals related to cell survival and/or proliferation and cancer metastasis. In the present study we have investigated whether deregulation in CXCR4 signaling (as a consequence of deregulated expression of CXCL12) modulate the metastatic potential of cervical carcinoma cells. We demonstrate that CXCL12 is frequently down regulated and its promoter is hypermethylated in cervical cancer cell lines and primary tumor biopsies. Exogenous treatment of cervical cancer cell lines (HeLa, SiHa and C-33A) with recombinant CXCL12 inhibited the metastasis promoting cell migration, cell invasion and anchorage independent cell growth events. Although this study will need further in vivo validation, our observations suggest that (a) silencing of CXCL12 in cervical cancer cells may be critical in migration and invasion, the key events in cancer cell metastases; (b) cervical cancer cells having down regulated CXCL12 are more prone to being attracted to CXCL12 expressed at secondary sites of metastases; and (c) CXCL12 inhibits anchorage independent cell growth via anoikis. These findings suggest the tumor suppressor functions of CXCL12 in cervical cancer.

Entities:  

Keywords:  Anchorage independent cell growth; CXCL12; Cell invasion; Cell migration; Cervical cancer; Promoter hypermethylation

Mesh:

Substances:

Year:  2016        PMID: 26970955     DOI: 10.1007/s10585-016-9787-9

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  Comprehensive molecular cytogenetic characterization of cervical cancer cell lines.

Authors:  Charles P Harris; Xin Yan Lu; Gopeshwar Narayan; Bhuvanesh Singh; Vundavalli V V S Murty; Pulivarthi H Rao
Journal:  Genes Chromosomes Cancer       Date:  2003-03       Impact factor: 5.006

2.  Tissue extraction of DNA and RNA and analysis by the polymerase chain reaction.

Authors:  D P Jackson; F A Lewis; G R Taylor; A W Boylston; P Quirke
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

Review 3.  Chemokines and cancer.

Authors:  Albert Zlotnik
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

4.  Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.

Authors:  M K Wendt; A N Cooper; M B Dwinell
Journal:  Oncogene       Date:  2007-09-03       Impact factor: 9.867

5.  Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.

Authors:  Costanza Bogani; Vanessa Ponziani; Paola Guglielmelli; Cristophe Desterke; Vittorio Rosti; Alberto Bosi; Marie-Caroline Le Bousse-Kerdilès; Giovanni Barosi; Alessandro M Vannucchi
Journal:  Stem Cells       Date:  2008-05-29       Impact factor: 6.277

6.  Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.

Authors:  Gopeshwar Narayan; Hugo Arias-Pulido; Subhadra V Nandula; Katia Basso; Dorcas D Sugirtharaj; Hernan Vargas; Mahesh Mansukhani; Jeannine Villella; Larissa Meyer; Achim Schneider; Lutz Gissmann; Matthias Dürst; Bhavana Pothuri; Vundavalli V V S Murty
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

7.  Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1α, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells.

Authors:  D Yoshida; R Nomura; A Teramoto
Journal:  J Neuroendocrinol       Date:  2009-05       Impact factor: 3.627

8.  CXCR4/CXCL12 expression and signalling in kidney cancer.

Authors:  A J Schrader; O Lechner; M Templin; K E J Dittmar; S Machtens; M Mengel; M Probst-Kepper; A Franzke; T Wollensak; P Gatzlaff; J Atzpodien; J Buer; J Lauber
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

9.  Gene expression changes in residual advanced cervical cancer after radiotherapy: indicators of poor prognosis and radioresistance?

Authors:  Zhi-chao Fu; Feng-mei Wang; Jian-ming Cai
Journal:  Med Sci Monit       Date:  2015-05-05

10.  Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer.

Authors:  Yu Huang; Jia Zhang; Zhu-Mei Cui; Jing Zhao; Ye Zheng
Journal:  Chin J Cancer       Date:  2012-09-10
View more
  5 in total

1.  Differences in chemotaxis of human mesenchymal stem cells and cervical cancer cells.

Authors:  Yizuo Song; Ruyi Li; Miaomiao Ye; Chunyu Pan; Lihong Zheng; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Apoptosis       Date:  2022-07-18       Impact factor: 5.561

2.  PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer.

Authors:  Hongfang Li; Gaogao Sun; Chang Liu; Jing Wang; Rong Jing; Jie Wang; Xiaohuan Zhao; Xiaoyan Xu; Yongxiu Yang
Journal:  Onco Targets Ther       Date:  2017-11-27       Impact factor: 4.147

3.  Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration.

Authors:  Benoît Romain; Radhia Benbrika-Nehmar; Laetitia Marisa; Michèle Legrain; Viviane Lobstein; Attila Oravecz; Laetitia Poidevin; Cyril Bour; Jean-Noël Freund; Isabelle Duluc; Dominique Guenot; Erwan Pencreach
Journal:  Oncotarget       Date:  2017-06-13

4.  Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.

Authors:  Shuoling Chen; Chang Gao; Yangyuan Wu; Zunnan Huang
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

Review 5.  Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.

Authors:  Aïssata Aimée Goïta; Dominique Guenot
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.